Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Indutrade, Audiocast, Q3'25

By Inderes10/21/2025, 7:30 AM
Indutrade

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Bo Annvik
00:02 - 09:09

Welcome and good morning on our behalf as well. As usual, let's start with the overall highlights of the report. In terms of the demand situation, the order intake improved compared to last year. Four out of five business areas and more than half of the companies grew organically. Demand from customers within medical technology and pharmaceuticals was strong, and we also saw improvements in several of the larger customer segments. Net sales decreased by 2% in total, with a 1% organic decline. The EBITA margin came in strong at 14.6%. Our companies were also successful in terms of working capital efficiency, and the inventory reductions continued during the quarter. We had a very successful quarter in terms of acquisitions, welcoming six companies during the quarter. Looking more specifically at the order intake and sales trends. Demand was stronger than last year, with improvements in many companies, customer segments, and geographies. Despite the high order intake, the book-to-bill ratio was slightly negative, partly due to seasonal variations. There were still continued variations between companies and segments, with the strongest growth within medical technology and pharmaceuticals. The demand within the energy sector was at a high level but aggregated slightly lower than last year. Notably, order intake for companies with customers in infrastructure, construction, and engineering improved compared to last year. In terms of sales, they declined by 2% during the quarter due to currency headwinds, divestments, and a 1% organic decline. While acquisitions contributed positively. There was no impact from the number of working days during the quarter. The organic sales development is primarily explained by the strong references within the business area of life science. The strong reference is linked to sales to Novo Nordisk, which had an organic sales impact of 2% on the group in the quarter. Excluding sales to Novo Nordisk, the organic growth would have been 1% on group level aggregated. More than half of the companies grew organically during the quarter. Moving into sales per geographical market. Sales to Sweden were up compared to last year, with improvements in most of the larger customer segments. Sales in Denmark were down, mainly due to strong sales to Novo Nordisk. During the same period last year, Finland and Norway were aggregated as flat year over year compared to the rest of Europe. Sales growth was strong in the Benelux. Within the process, industry, and energy sectors. UK and Ireland also improved with slightly better demand within general engineering and good development within flow technology. Products. Sales development was flat in Germany, Switzerland, and Austria. In North America and Asia, sales are slightly volatile, and the development can fluctuate with single projects. In North America, we had a challenging reference due to larger deliveries of valves for power generation in the same period last year, and some of the companies in BA Technology and System Solutions continue to have weaker development due to hesitation from US customers amidst the tariff situation. Sales in Asia improved compared to last year due to strong sales of valves for power generation and also within the marine segment. The total EBITDA decreased by 3% to 1.1 billion, corresponding to an EBITDA margin of 14.6%, slightly lower than 14.8% last year, but still a high level and a clear step up sequentially from 13.7% in Q2. We had a record high Q3 gross margin of 35.5%. Margin accretive acquisitions and divestments supported as well, but the EBITA margin was dampened by lower organic sales and somewhat higher organic expenses. In terms of the organic expenses, there was around a percentage point year-over-year increase in absolute numbers. I would say that the expense situation overall is under control. There is still a cluster of companies which can improve somewhat. However, the majority of the companies are growing, and it's likely we'll see some expense increases linked to this. Looking at net sales per business area, as mentioned, the same number of working days in the quarter, but a slightly lower order book coming into the quarter and strong references resulted in a slightly negative organic sales development for the group as a whole. Organic sales were up 3% in the business area of process, energy, and water. For instance, many other Swedish companies experienced good development, and the Finnish process industry also saw improvements in technology and system solutions. Sales were unchanged. Infrastructure and construction and industrial and engineering continued to be impacted by the weak general business climate. Business area Life Science had a 5% organic sales drop due to the strong sales to Novo Nordisk in the same period last year. Excluding this, life science would have had a positive organic sales growth of 6%. The business area continued to show good development, with growth in the single-use sector and also in medical technology distribution during the quarter. The EBITA margin improved in two of the five business areas, with the most significant improvement in infrastructure and construction, mainly due to acquisitions and divestments. Life Science managed to improve the margin despite the lower organic sales. They had strong gross margin development due to a favorable product mix, some currency tailwind, and good work on pricing in many companies. In the other three business areas, the EBITDA margin was basically in line with last year. Since the beginning of the year, we have added ten new companies to the group, with total annual sales of approximately 1.1 billion SEK. After a somewhat slower start to the year, acquisitions accelerated in the third quarter. The acquisition pace improved in the third quarter with six acquisitions completed in the fourth quarter. We have so far welcomed one company. We are working with several projects in different stages, so we look forward to welcoming a few more companies in the remainder of the year. Our new organization with business segment leaders is also generating more internal leads than before. Looking at the longer trend, more importantly, we are incrementally increasing the number of acquisitions per year, as can be seen in the yellow line to the left. Although the number of acquisitions per year can be a bit volatile. Looking at the bridge effects from acquisitions, over the last 12 months, we have added 140 million SEK to the group's EBITDA in 2025. Five. Furthermore, we can also see that the acquisitions are margin accretive, with an accumulated EBITDA margin of 16.4% for the quarter and over 17% rolling 12 months. By that, I hand over to Patrik to comment more on the financials.

Patrik Johnson
09:10 - 15:48

Yes. Thank you. Bo. Yes. Total growth for orders and sales in the quarter was plus three and minus two, respectively. Year to date orders have also increased by 3% while sales are slightly down by 1%. Book-to-bill ratio is close to one, slightly below. But as Bo said, impacted by seasonal variations during the quarter. Year to date, it is above one. In quarter three, we further improved the gross margins, reaching 35.5% versus 34%, so a really good improvement. However, last year's figure was impacted by inventory write-downs in a few companies, so the underlying improvement was not as high as shown in these numbers, but still a clear improvement on the year-to-date basis. Our gross margin remains ahead of last year's level. EBITDA decreased by 3% in the quarter and is also down 3% year-to-date. If you look at the margin, the EBITDA margin for the quarter was 14.6% compared to 14.8% last year. Good improvement. Really good improvement from quarter one and quarter two. We had some non-operational one-off items during the quarter connected to earnouts and goodwill. Write down, as we have from time to time. But the net effect during the quarter was close to zero. As a side note, as maybe a few of you have noted, group items appear as unusually high this quarter. I would say this is, however, the wrong conclusion. It's a bit unfortunate, but it actually relates mostly to our routine concerning management fees, which before, for tax reasons, were pushed out to the business areas. This was last year done in quarter three, which lowered group items last year. So, and that's the main reason for the increase. Yes. Continuing further down in the P&L, finance net decreased 31% in the quarter and 16% year to date because of both lower interest rates and also lower debt level. Tax cost increased 17% in the quarter and 3% year to date. The high tax costs are due to an unusually low tax level last year, and that came from a one-off situation. It was due to an operational one-off situation we had last year. Earnings per share decreased by 4% in the quarter and also year to date. And I will show a graphical trend on the following slides. Return on capital employed is at 19%, and that's unchanged from last year. But slightly below our targets. Operational cash flow remained unchanged at a strong, high level. I will also elaborate on that in the coming slides. Net debt to EBITDA at the end of the quarter is at 1.4 versus 1.6 last year. So there was an improvement in that area as well. So moving on to the cash flow. Cash flow, as I said, remained unchanged from the same period last year and is at a good level. And total organic working capital was down in the quarter versus last year. Despite more normalized inventory levels, our companies actually managed to reduce them further sequentially. And also compared to last year, cash conversion has continued at a high level, currently trending on a rolling four-quarter basis at a level of 133 compared to net profit less CapEx. That's a good and strong level. We're closely monitoring the working capital efficiency. Despite the lower organic sales, the ratio in relation to sales improved. Again, during the quarter, compared to last year. Continuing to the earnings per share, it amounted to 1.85 compared to 1.92 last year. The decline is, of course, mainly related to the lower operational result. Lower interest costs continued to compensate, but were offset by the higher tax costs I talked about earlier. Zooming out, looking at the longer perspective, the average growth in the three and five-year rolling four-quarter perspectives was plus two and 10%. Lastly, regarding the financial position, we believe it remains strong and solid. The interest-bearing net debt decreased versus last year from 8.8 billion to 1.18 billion. 1 billion, mainly due to the strong operational cash flow combined with a slightly lower acquisition pace. During the year, our net debt ratios are stable and low. From a historical perspective, the net debt to equity ratio was at 48% compared to 56% last year. And at that, EBITDA was 1.4 versus 1.6. And if you exclude earnouts, it is then 1.3 at the end of quarter three this year and 1.4 last year. To summarize, our financial position is strong. And that is, of course, a good foundation for continued value-accretive acquisitions and also organic growth initiatives. Then I hand it back over to you.

Bo Annvik
15:49 - 18:28

Thank you. We have also included a slide elaborating a bit on, you can say, the broader cost situation and its link to headcount. So, as we have discussed for several quarters, demand and sales in some of our companies have been challenging, and expenses, headcount, and productivity have become more focused. All of these companies are implementing cost reduction activities, including headcount reductions. However, more than half of our companies are still growing. And for these companies, it is prudent to continue with growth plans and to selectively add headcount and costs. This slide shows the organic change in FTEs among companies with growing and declining order intakes respectively. By the end of Q3, headcount was reduced by 6% compared to last year in the companies with declining order intake. Further reductions are planned for Q4. In the companies with a positive order development, we have increased headcount by 2%. In a decentralized organization like Indutrade, there is no one-size-fits-all approach. Rather, individual actions are being implemented continuously. Overall, our companies and MDS are managing the challenging market situation in a good way. However, there is also a strong principle embedded in our culture to continuously improve. By that, we sum up the key takeaways of the presentation. The positive demand development continues. Order intake is up 3% organically. Slightly lower organic sales, mainly due to challenging comparisons. Strong EBITA margin of 14.6%. Companies continue to actively work on adapting costs to their respective market situations. Market uncertainty remains for the upcoming quarter. Slightly larger order book and higher acquisition pace provide some comfort about the financial performance trend. Ten companies acquired so far in 2025, and still a good pipeline. All in all, a strong platform for long-term, sustainable, profitable growth. By that, we say thank you and open up for potential questions.

Operator
18:29 - 18:46

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Carl Ragnerstam from Nordea. Please go ahead.

Carl Ragnerstam
18:49 - 19:32

Good morning. It's Carl. I have a couple of questions from my side. Firstly, thank you for sharing. Slide 14. Quite interesting. Can you talk a little bit about your plans ahead on this slide as well? I mean, we can see a -6% change at the companies with declining order intake. It sounded like you would like to continue to drive it down even further. And also the companies growing by 2%. I mean, with positive order intake growth, will you try to keep it at around 2% or will it. Yeah. What is the plan there? Obviously, you want to achieve operating leverage. I assume you will strive to keep it as low as possible. Right?

Bo Annvik
19:32 - 21:27

So yeah, good question and relevant question. It's the answer. I mean, broadly, Indutrade is an aggregation of over 200 companies, as you know, and it's sometimes difficult to have a clear, elaborate view to convey to you linked to this. But as you say yourself, we will continue to reduce costs in some companies with challenging market situations. There have been steps taken already up until now. However, there are actually situations where actions were taken, perhaps already during Q3. And the effects of those actions will be seen more in Q4. So there is a cluster of companies where cost reductions will continue. For the majority of the companies, there are small clusters of clear growth cases, and they grow quite significantly. We have a handful of companies that have experienced significant changes in their perspective, including the addition of many new colleagues. But the broader majority is, as you say, expected to grow more or less in line with inflation. I would say in that cluster where there is more normal, more normalized sort of organic growth development.

Carl Ragnerstam
21:29 - 22:05

For the majority of companies, there are small clusters of clear growth cases, and they grow quite significantly. That is very clear. And for the majority of the companies, there is a small cluster of clear growth cases, and they grow quite significantly. And on order intake. It's good to see that orders are picking up in pace. I guess two questions on that are, firstly, if you see the quite healthy momentum continuing so far, both during the latter part of the quarter and now in October. And secondly, we saw quite strong order intake in life science. Could you please assist us in dividing it by subsegments there? Thank you.

Bo Annvik
22:07 - 25:43

Yeah, we are all eagerly waiting for the market pickup more broadly and really looking for signs to hold on to and build on. As you know, the broad Indutrade organization views the glass as half full. They are definitely more optimistic than the other way around. I think it's slightly. I would say that it's slight. Slight, slight sort of. Overall, there are positive views and attitudes towards the market broadly. However, there is still more of a flat, broad trend. Also, a few segments are decreasing now, I think. So it's more a sideways movement, but still some optimistic points here and there. I think you already know most of them, apart from life science, which I will comment on more separately, as you asked for. There are pockets in water and wastewater that are clearly positive. Defense-related areas. Aerospace-related areas. And now I would say that inventory levels broadly in many segments have gone down. Even if projects have been moved forward, a lot of companies within complicated process industries need to continue with essential maintenance projects, but also improvement projects, in order to run their operations efficiently. So, there are maybe not green fields, but definitely brownfield improvements, which need to take place here and there. We see that increasingly more, I would say. So, I don't want to say that the market has turned broadly. It's more of a sideways movement, but. Nonetheless, there's a bit more optimism. I would say when we talk to our companies in terms of life science, it's clearly the single-use segments where the inventory levels have also decreased. They are ordering, and there are a number of more complicated diseases which need lower volumes, both developed and produced in these single-use systems in the life science area. So I think there is a good underlying growth for several years to come in that area. But then there are also areas in the medical technology sector where we see good momentum. I would say, but that's difficult to express in segments because it's more a collection of individual companies rather than clear segments. We have that there. So, it's a bit more broadly med tech related, I would say.

Carl Ragnerstam
25:45 - 26:16

That's very clear. And the final one, if I may, is on life sciences again here. Strong margin development despite the tough Novo Nordisk comps. Clearly. Of course, you touched upon single use as one effect. Could you help us give any insights into how much it grew organically in the quarter? Single use, either on orders or top line? Uh, but also what effect it had on margins. Thus, there are maybe not green fields, but definitely brownfield improvements that need to take place here and there.

Bo Annvik
26:17 - 28:10

I can't give you specific numbers on that, but it's not only single use that is contributing to this. It's also clearly the medical technology area. So, it's a combination, I would say. I should also comment on Novo Nordisk. We have, you know, absolutely less than five companies relating to Novo Nordisk in a significant way. And our companies are still, even if volume has gone down significantly to that customer, those companies are still above Indutrade's average EBITA margin. So they are still managing the situation well margin-wise. In terms of Novo Nordisk, what we are picking up is that the large factory capacity building project they have in Kalundborg, where some of our companies are involved, will continue. So there will also be, going forward, some significant order intake at some point linked to further capacity expansion projects. So, it's not all day-to-day business; with Novo Nordisk, it's significantly down because they have reduced, what is it, 5000 headcount in Denmark, so companies don't have the same relationships. It's a bit of a 'wait and see' mode for some of those projects. But some of the key big capacity building projects will move on as we understand it.

Carl Ragnerstam
28:12 - 28:14

Okay, that's very clear. Thank you.

Bo Annvik
28:15 - 28:16

So there will also going forward be some significant order intake at some point, linked to further capacity expansion projects.

Operator
28:20 - 28:25

The next question comes from Carl Boqvist from ABG Sundal Collier. Please go ahead.

Carl Boqvist
28:27 - 28:55

So there will also, going forward, be some significant order intake at some point linked to further capacity expansion projects. Good morning. My first question is on. I would say both Pao and SE. It seems like especially in SE, order intake has been good in both Q2 and Q3. And I was just curious to hear about the comments you, I believe, made earlier in the year right after Liberation Day regarding customer decision inertia, if we call it that, and whether this has improved.

Bo Annvik
28:57 - 30:44

Or it's a relevant question for that business here. It's our most international business area and the area with the most customers in the North American, specifically the US market. And they still feel that there is. There are some difficulties in closing projects linked to the tariff situation. Most of that business is indirect for us, I would say. So it's more that maybe we have Western European customers who sell into the US than direct sales. But there is also some direct impact and. There is still a little bit of a wait-and-see type of mode in that market, I would say. I think as a business area they are picking up, but also from slightly lower references. I think so. So, they are moving in the right direction. But a lot of those customers TS are related to industrial engineering companies. It's still not going to be a super significant pickup, I don't think, but a somewhat improving market situation, hopefully as the tariff situation stabilizes and at least companies can plan for certain investments with more reliability around it.

Carl Boqvist
30:46 - 30:59

Understood. And my second question is just regarding M&A and the acquisition landscape, specifically regions you find particularly active or interesting at this point in time.

Bo Annvik
31:03 - 32:07

I would say that Western Europe, broadly speaking, including the Nordics, is still very interesting. Germany, we see a growing effect from Indutrade becoming more and more known step by step. And we also have a full-time resource in Germany now since a while back. We also have a full-time resource there since some time ago. He's providing more leads every quarter, I would say. We are maybe a little bit more geographically hesitant regarding the UK, but otherwise, I would say Western Europe has pockets of opportunities everywhere.

Carl Boqvist
32:09 - 32:11

Understood. That's all from my side. Thank you.

Bo Annvik
32:12 - 32:12

Thank you.

Operator
32:17 - 32:22

The next question comes from Zeno England Ricciuti from Handelsbanken. Please go ahead.

Zeno England Ricciuti
32:24 - 32:39

Yes. Good day. Thank you for taking our questions. I've also got a couple on M&A just following up. Why are you hesitant about the UK? If it's related to the underlying market.

Bo Annvik
32:40 - 33:35

Yes. I think there are fewer and fewer successful large engineering and industrial companies in the UK. From a regional and global perspective. So I think you need to be in a context where the broader environment is financially successful and growing. And unfortunately, I think there's a bit less of that in the UK compared to other Western European countries. So it is more linked to that, I would say. But there are obviously still real jewels we can find in the UK as well. So it's not that we have completely shut down in terms of looking for companies in the UK, but the broader business environment is a bit more challenging, I think.

Zeno England Ricciuti
33:37 - 34:06

Understood. And also on the M&A side, when we look at the acquisition pace, it has been quite good in Q3, especially compared with the first half of the year. If we relate this to the last time you paused the acquisition machine, so to say, at the end of 2023, we saw a bit of a catch-up effect in the beginning of 2024. Or would you say that what we're seeing now is part of a catch-up?

Bo Annvik
34:08 - 35:28

Yes. I think it's partly been a catch-up, which we have also communicated earlier, that we expected in quarter three. But we also, as I briefly commented in my presentation, noted that the new organization with a platform of defined segments and appointed segment leaders, since a bit more than a year and a half back, are getting more accustomed, to use a Swedish expression. And have had more time to build pipelines, create relationships, and so on and so forth. I feel like comfort might not be the right word, but I'm optimistic about what this investment in resource organization is potentially generating as we move forward. So, it's two things. It's a catch-up and to some extent, it's also the effect of a stronger acquisition resource machinery going forward now.

Zeno England Ricciuti
35:30 - 35:50

Very clear. And regarding the new organization, would you say that in recent times your expectation on when they are fully up to speed has changed, or is it a couple of years until that is fully operational?

Bo Annvik
35:51 - 36:18

Yes, it's people. They are all individuals. Some pick up extremely fast as they have a little more experience, while others are a bit newer to the situation. So yeah, it's probably difficult to specify a time on it. But we are not. We're definitely not operating at full speed with regard to this at the moment. That's still to come. I would say.

Patrik Johnson
36:19 - 36:45

And also, if I can comment, internal lead generation is really long-term work. Not all companies you contact are, of course, for sale, and you need to build up the pipeline and, over time, it generates more and more acquisitions. And so, even if they are working in the right way with good pace, it takes time for it to result in closed transactions.

Bo Annvik
36:46 - 36:47

That's correct.

Zeno England Ricciuti
36:49 - 36:51

Very good. Thank you. That's all for me.

Bo Annvik
36:52 - 36:52

Thanks.

Operator
36:57 - 37:01

The next question comes from Johan Dahl from Danske Bank. Please go ahead.

Johan Dahl
37:02 - 37:29

Yes. Good morning everyone. Just two quick questions. Firstly, on the gross margin, you talked about the pricing actions in life science. Looking at the other parts of the group, is that also showing a positive trend, or is it flat or perhaps even more challenging in those areas? Secondly, I was just wondering about the portfolio, as you made some divestitures this quarter. Is there more portfolio pruning activity going on at Indutrade right now? The next question comes from Johan Dahl from Danske Bank.

Bo Annvik
37:32 - 38:36

I think our companies, in general, are extremely good at transferring costs to the customers and defending the gross margin. So I think we expect to be at a good gross margin level going forward. So, nothing dramatic to plan for in terms of an unexpected decline or something like that. So I think we are at a good level and we will hopefully defend and stay at this good level. In terms of pruning divestments, I think. We have probably completed most of those actions in the short term. You can never say never, but most have been done in the short term and not the same sort of number or effects going forward.

Patrik Johnson
38:39 - 39:41

All right. Would you like me to elaborate on the gross margin a little bit? I think we saw a positive development in the majority of companies across most business areas. So, maybe life science stands out a little bit, but it's certainly not the only contributor. And then pricing is, of course, one important thing. And then mix, and I think we've seen a positive mix with, you know, stronger gross margins. Some company sectors have been improving slightly more than others. That's an important piece of the puzzle. And then, also currency. Actually, since we have a lot of trading companies in Sweden with stronger currency positions now, importing goods in dollars and euros is improving the margin slightly. So that's also a contributor. Yes.

Johan Dahl
39:41 - 39:42

Good. Thanks.

Operator
39:49 - 39:53

The next question comes from Robert Redin from NAB Carnegie. Please go ahead.

Robert Redin
39:56 - 40:32

Yes. Hi. Patrick, I just wanted to revisit the parent group overhead costs in the EBITA. Table 82 million. You said last year was low due to some internal factors. Cost, cost, cost development. But 82 is still a high number. Is this a number we should be expecting going forward on that line?

Patrik Johnson
40:32 - 40:50

Yes. Yeah, I would say that the 82 is more relevant as an ongoing quarterly figure, maybe slightly higher. Maybe it is around 70 or so, which would be a sort of sustainable quarterly level. I would say.

Robert Redin
40:54 - 41:21

All right. Perfect. And then generally on costs, you had that slide showing the DFT reductions. But in Q3, did you have much of an impact from those reductions? I mean, that was the reduction from a year ago. When did that take effect? And in terms of year-over-year cost development? Did it have full effect, half effect, or not much impact in Q3 this year?

Patrik Johnson
41:23 - 42:05

I'm not sure if I fully understood your question, but if you look at total cost, total overhead cost, and SG&A, there is also more operational or manufacturing related overhead. So, ideally we want this to go down slightly further, but I think we have it under good control. And I think you should expect it to be going sideways going forward.

Robert Redin
42:09 - 42:33

All right. Yes. Because my question was, if you combine all of the cost items between gross margin and EBITA, they were growing quite a lot year over year. I was thinking this 6% FTE reduction you had in the businesses with weaker demand maybe didn't have much of a cost effect in Q3 because of the timing.

Patrik Johnson
42:36 - 43:38

I think the reduction of people is something that. End of quarter three compared to the end of quarter three last year. So that's the timeframe for that slide and that number. But I mean, given that we have also more things on the headcount side that we have initiated and that will be implemented or executed during quarter four. And these things will, of course, also have a cost effect. I was thinking this 6% FTE reduction you had in the businesses with weaker demand maybe didn't have much of a cost effect in Q3 because of the timing. During the quarter. So I think from that perspective, we will realize lower costs. But then there are also other things regarding companies that are growing; they are also doing slightly more activities, etc. . And considering all this, I don't want you to expect a significant reduction during quarter four. So I think it's more fair and realistic to estimate a sort of sideways movement of costs.

Robert Redin
43:42 - 43:44

All right. I was thinking, the 6% FTE reduction you had in the businesses with weaker demand may not have had a significant cost effect in Q3 because of the timing. I was thinking about the 6% FTE reduction you had in the businesses with weaker demand, which maybe didn't impact costs much in Q3 due to timing.

Operator
43:50 - 44:03

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Mats List from Kepler Cheuvreux. Please go ahead.

Mats List
44:05 - 44:23

Yes. Hi. I was thinking this 6% FTE reduction you had in the businesses with weaker demand maybe didn't have much of a cost effect in Q3 due to the timing. Three quick ones from my side. You mentioned the different factors that affected your orders, including the price mix and currencies. Could you be a bit more specific about prices and volumes?

Bo Annvik
44:27 - 44:31

I think it's difficult for us to be more specific there, but.

Patrik Johnson
44:33 - 44:59

But in general, we can say I think our companies are still increasing prices, but it's not at the levels we saw if you go back a couple of years. So it's more of the normal 1 to 3% increase per year. That's embedded in the numbers. However, we do not have an exact quarterly number.

Mats List
44:59 - 45:18

No, no. Then I. Well, just for support going forward. And what's your feeling about the comps going forward in the fourth quarter, year-over-year comparisons there? How do you feel about that?

Patrik Johnson
45:21 - 45:42

For the quarter, if you look at the top line, I think the references are normal to slightly lower. There isn't any significant change, but I would say it's slightly lower. Mm.

Mats List
45:44 - 46:09

Great. And finally, I mean, you mentioned the opportunities there and the list of acquisitions you have, and you mentioned the geographical opportunities. Could you say something about the opportunities in the different business areas? Where are you? I understand you can't be so specific, but.

Bo Annvik
46:09 - 47:03

Yes. No, but we obviously see opportunities to work with opportunities in all business areas. And sometimes they play out differently over time. I would expect life science to have a good momentum and a strong pipeline. All of them have a better pipeline, but, yeah. Life science is strong. I think the sectors of process energy and water are strong. Industrial engineering is also strong. Maybe somewhat. There are good pipelines in all five areas, but maybe those three stand out a little bit.

Mats List
47:05 - 47:07

Okay, great. Thanks a lot.

Bo Annvik
47:08 - 47:08

Thank you.

Operator
47:42 - 47:48

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Bo Annvik
47:49 - 47:55

Then we thank you for listening in and asking good questions and wish you a good day. Bye bye.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…